|
Physician-in-Chief, Department of Medicine, Jewish General Hospital
Director, Hypertension and Vascular Research Unit, Lady Davis Institute for Medical Research
Distinguished James McGill Professor and Associate Chair, Department of Medicine, McGill University
Dr. Schiffrin's Publications Indexed on PubMed
Dr. Ernesto L. Schiffrin (MD Buenos Aires '69, PhD in Experimental Medicine, McGill University '80) is Physician-in-Chief, Department of Medicine, at the Jewish General Hospital; Director of the Hypertension and Vascular Research Unit, Lady Davis Institute for Medical Research; as well as Distinguished James McGill Professor and Associate Chair, Department of Medicine, McGill University. Dr. Schiffrin also directs the Cardiovascular Prevention Center at the hospital, where his clinical research is carried out. Dr. Schiffrin was previously Professor of Medicine at the University of Montreal (until December 2005), Director of the Multidisciplinary Research Group in Hypertension of the Medical Research Council of Canada (later Canadian Institutes of Health Research) and the Hypertension Clinic at the Clinical Research Institute of Montreal (IRCM), and staff member in the Division of Internal Medicine, Hôtel-Dieu Hospital.
Dr. Schiffrin has served on committees of the Canadian Heart Foundation and Medical Research Council of Canada (MRC). He was a member (1987-1989), then Chair of the Cardiovascular B grants committee of the MRC (1989-1992). In June 2008, Dr. Schiffrin co-chaired the Working Group on Target Organ Damage in Hypertension for the National Heart Lung and Blood Institute (NHLBI), which prepared goals for the NIH to launch RFAs in the field of hypertension, and which have been posted on the NHLBI website.
Dr. Schiffrin was the Associate Editor of the American Heart Association (AHA) journal Hypertension since August 2003 till September 2015. Dr. Schiffrin was elected as a Fellow of the Royal Society of Canada in 2006. He is the recipient of the 2007 Irvine Page-Alva Bradley Lifetime Achievement Award of the High Blood Pressure Research Council of the American Heart Association and the 2010 Bjorn Folkow Award of the European Society of Hypertension. The Governor General of Canada appointed Dr. Schiffrin a Member of the Order of Canada in 2010 for his important contributions to the study of hypertension, notably through his research on the mechanisms underlying high blood pressure, as well as for his leadership roles in scientific committees and societies. Dr. Schiffrin received the 2011 Excellence Award for Research in Hypertension of the American Heart Association. The citation of the award reads: For his pioneering translational work leading to discovery of mechanisms involved in the remodeling of small resistance arteries in experimental and human hypertension. His ground-breaking research demonstrated that antihypertensive therapy electively causes regression of vascular remodeling in hypertensive patients. His seminal studies on angiotensin II, aldosterone and endothelin have elucidated the importance of these hormones in the vascular biology of hypertension.
Dr. Schiffrin was named the 2013 American Society of Hypertension (ASH) Distinguished Scientist and received the Robert Tigerstedt Award in May 2013 in San Francisco, CA, for his outstanding achievements in the field of hypertension and his contribution to both endocrinology and circulation. In October 2013 the Canadian Cardiovascular Society (CCS) awarded Dr. Schiffrin the 2013 CCS Research Achievement Award, one of the most prestigious honours bestowed by the Society, for his contribution to Canadian cardiovascular health and care and invited him to present on his research at its annual meeting in Montreal. On October 19, 2013 Dr. Schiffrin was elected President of Hypertension Canada. In July 2015, Dr. Schiffrin was awarded a Foundation grant from the CIHR for $3.25 million for 2015-2023 to pursue his research on hypertension. In November 2015, Dr. Schiffrin received the Canadian Society of Clinical Investigation's 2015 Distinguished Scientist Lecture and Award. In January 2016, Dr. Schiffrin became Editor-in-Chief of the American Journal of Hypertension. In September 2016, Dr. Schiffrin received the 2016 Margolese National Heart Disorders Prize. In November 2017, Dr. Schiffrin received the 2017 Prix Galien Canada - Research Award. In December 2019, Dr. Schiffrin received the Distinguished James McGill Professor award which recognizes a late-career scholar's sustained scholarship of world-class caliber, international leadership and outstanding research record. In 2021 Dr. Schiffrin received the 2021 Franz
Volhard Award of the International Society of Hypertension and was named 2021
Distinguished Scientist of the American Heart Association.
Major Research Activities
Clinical and experimental hypertension, role of vasoactive peptides (angiotensin, endothelin) and their intracellular signal transduction, resistance arteries in cardiovascular disease and more specifically in clinical and experimental hypertension, role of endothelium, cardiovascular hypertrophy and vascular remodeling, clinical pharmacology of hypertension, genetic determinants of hypertension and vascular remodeling, microRNAs and immune system in hypertension. Next generation and single cell sequencing.
Recent Publications
(Selected peer-reviewed publications out of a total of 617. H-index: 133)
Ouerd S, Idris-Khodja N, Trindade M, Coelho SC, Neves MF, Jandeleit-Dahm KA, Paradis P, Schiffrin EL. Endothelial Cell-Restricted Endothelin-1 Overexpression Worsens Atherosclerosis and Immune Cell Infiltration in Type-1 Diabetes via NOX1. Cardiovasc Res. 2021;117(4):1144–1153. doi:10.1093/cvr/cvaa168. PMID: 32533834.
Berillo O, Ouerd S, Idris-Khodja N, Rehman A, Richer C, Sinnett D, Kwitek AE, Paradis P, Schiffrin EL. Chromosome 2 fragment substitutions in Dahl salt-sensitive rats and RNA sequencing identified Enpep and Hs2st1 as vascular inflammatory modulators. Hypertension. 2021;77:178-189. DOI: 10.1161/HYPERTENSIONAHA.120.15690. PMID: 33161775.
Berillo
O, Huo K-G, Fraulob-Aquino JC, Richer C, Briet, M, Boutouyrie P, Lipman ML,
Sinnett D, Paradis P, Schiffrin EL. Circulating let-7g-5p and miR-191-5p
are independent predictors of chronic kidney disease in hypertensive patients.
Amer J Hypert. 2020;33(6):505–513. Doi: 10.1093/ajh/hpaa031. PMID: 32115655.
Huo K-G, Richer C, Berillo O, Mahjoub N, Fraulob-Aquino JC, Barhoumi T, Ouerd S, Coelho SC, Sinnett D, Paradis P, Schiffrin EL. miR-431-5p knockdown protects against angiotensin II-induced hypertension and vascular injury. Hypertension. 2019;73:1007–1017. DOI: 10.1161/HYPERTENSIONAHA.119.12619. PMID: 30929512.
Coelho SC, Berillo O, Ouerd S, Fraulob-Aquino JC, Caillon A, Barhoumi T, Offermanns S, Paradis P, Schiffrin EL. Three-month endothelial human endothelin-1 overexpression causes blood pressure elevation and vascular and kidney injury. Hypertension. 2018;71:208-216. DOI: 10.1161/ HYPERTENSIONAHA.117.09925.PMID: 29133362.
Caillon A, Mian MOR, Fraulob-Aquino JC, Huo K-G, Barhoumi T, Ouerd S, Sinnaeve PR, Paradis P, Schiffrin EL. Gamma Delta T Cells Mediate Angiotensin II-Induced Hypertension and Vascular Injury. Circulation. 2017; 135:2155–2162. doi.org/10.1161/CIRCULATIONAHA.116.027058. PMID: 28330983.
|